Nuclear imaging of prostate cancer: Current status;Nuklearmedizinische diagnostik beim prostatakarzinom: Aktueller stand

Urologe - Ausgabe A

Volumn 46, Issue 11, 2007, Pages 1485-1499

  Reske, S N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

C 11 choline PET CT; Local relapse; Molecular imaging; MRT; Prostate carcinoma

Indexed keywords

CHOLINE C 11; CHOLINE F 18; CONTRAST MEDIUM; FLUORINE 18; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; HUMAN; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; SEMINAL VESICLE; TUMOR BIOPSY;

CARBON RADIOISOTOPES; CHOLINE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPH NODES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATIC NEOPLASMS; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36248958121     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-007-1572-6     Document Type: Article

References (46)

1. Jemal A, Murray T, Samuels A et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 53: 5-26
2. Nelson WG, Carter HB, DeWeese TL et al. (2004) Prostate Cancer. In: Abeloff MD, Armitage JO, Niederhuber JE et al. (eds) Clinical oncology, 3rd edn. Elsevier, Philadelphia, pp 2085-2148
3. 18F-Fluoride PET/CT. J Nucl Med 47: 287-297
4. 11C-Choline PET/CT. J Nucl Med 47: 1249-1254
5. Reske SN, Blumstein NM, Glatting G (2006) Weiterentwicklung der PET und des PET/CT beim Prostatakarzinom. Urologe A 45: 707-714
6. Reske SN, Blumstein NM, Glatting G (2006) PET und PET/CT in der Rezidivdiagnostik des Prostata-Karzinoms. Urologe A 45: 1240-1250
7. Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 199: 751-756
8. 18fluorine- labeled deoxyglucose. J Urol 155: 994-998
9. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45: 366-373
10. 11C-acetate positron emission tomography imaging and added value of image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 24: 2513-2519
11. Heerschap A, Jager GJ, Graaf M van der (1997) In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 17: 1455-1460
12. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39: 990-995
13. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61: 110-117
14. Schmid DT, John H, Zweifel R et al. (2005) Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 235: 623-628
15. Kwee SA, Wei H, Sesterhenn I et al. (2006) Localization of primary prostate cancer with Dual-Phase 18F-Fluorocholine PET. J Nucl Med 47: 262-269
16. 11)C- choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imag 34: 45-53
17. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 48: 56-63
18. Hricak H, Choyke PL, Eberhardt SC et al. (2007) Imaging prostate cancer: A multidisciplinary perspective. Radiology 243: 28-53
19. Carroll PR, Coakley FV, Kurhanewicz J (2006) Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol 8: 4-10
20. Prando A, Kurhanewicz J, Borges AP et al. (2005) Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 236: 903-910
21. Pathak AP, Gimi B, Glunde K et al. (2004) Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol 386: 3-60
22. Morakkabati-Spitz N, Bastian PJ, Meissner A et al. (2006) MR techniques for noninvasive diagnosis of prostate cancer. Urologe A 45: 702-705
23. 11C-choline PET. J Nucl Med 44: 331-335
24. Trabulsi EJ, Merriam WG, Gomella LG (2006) New imaging techniques in prostate cancer. Curr Urol Rep 7: 175-180
25. Harisinghani MG, Barentsz J, Hahn PF et al. (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348: 2491-2499
26. Harisinghani MG, Dixon WT, Saksena MA et al. (2004) MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. Radiographics 24: 867-878
27. Weissleder R, Elizondo G, Wittenberg J et al. (1990) Ultrasmall superparamagnetic iron oxide: an intravenous Contrast Agent for assessing Lymph Nodes with MR Imaging. Radiology 175: 494-498
28. Schauer AJ, Becker W, Reiser M, Possinger K (2005) The sentinel lymph node concept. Springer, Berlin Heidelberg New York, S 565
29. Vogt H, Wawroschek F, Wengenmair H et al. (2002) Sentinel lymph node diagnostic in prostate carcinoma: Part I: Technique and clinical evaluation. Nuklearmedizin 41: 95-101
30. Bott SR (2004) Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 7: 211-216
31. Pound CR, Partin AW, Eisenberger MA et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597
32. Boccon-Gibod L, Djavan WB, Hammerer P et al. (2004) Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 58: 382-390
33. Kuban DA, Levy LB, Potters L et al. (2006) Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65: 1487-1493
34. Heinisch M, Dirisamer A, Loidl W et al. (2006) Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imag Biol 8: 43-48
35. Kotzerke J, Prang J, Neumaier B et al. (2000) Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27: 1415-1419
36. 11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42: 25-30
37. 11C-Acetate PET Imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med 44: 549-555
38. 18F]fluorodeoxyglucose-positron emission tomography. J Urol 169: 1337-1340
39. 11C-Choline positron emission tomography in prostate cancer: Primary staging and recurrent site staging. Urol lnt 74: 214-220
40. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imag, Epub ahead of print (in press)
41. 18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33: 1387-1398
42. Sandblom G, Sörensen J, Lundin N et al. (2006) Positron emission tomography with C11-Acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67: 996-1000
43. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imag 34: 185-196
44. 11C]Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imag (in press)
45. 18F PET. J Nucl Med 40: 1623-1629
46. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42: 1800-1804